FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer

Exclusion Criteria

• •Inability or unwillingness to provide informed consent to the study
• •Participants currently undergoing neoadjuvant chemotherapy/endocrine therapy or those who have received chemotherapy/endocrine therapy within 6 months prior to the MRI
• •Participants who have had neoadjuvant chemotherapy/endocrine therapy, surgical intervention, or radiation for the current biopsy-proven malignancy
• •Participants with breast expanders
• •Participants who are or might be pregnant or lactating
• •Participants with a contraindication to gadolinium based contrast agents, including allergy or impaired renal function (per University of Wisconsin Health Guidelines)
• •Participants with a history of allergic reaction attributable to compounds of similar chemical or biologic composition to FFNP
• •Participants in liver failure as judged by the patient's physician
• •Participants with standard contraindications to MRI, including claustrophobia and metallic implants incompatible with MRI
• •* The subject has their own prescription for the medication
• •* The informed consent process is conducted prior to the self-administration of this medication
• •* They come to the research visit with a driver
• •Participants unable to lie prone for 30 minutes for imaging